Ovid Therapeutics's three largest insider shareholders as of April 28, 2026 are Jeremy M Levin (Executive Chairman, 3.74Mn shares), Amit Rakhit (President And Cmo, 726.82K shares), Amit Rakhit (President And Cmo, 726.82K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Jeremy M Levin | Executive Chairman | 3,735,048 | 0 | 25 Mar, 2026 |
| Amit Rakhit | President And Cmo | 726,823 | 0 | 16 Jul, 2021 |
| Amit Rakhit | President And Cmo | 726,823 | 0 | 16 Jul, 2021 |
| Stelios Papadopoulos | - | 217,578 | 0 | 09 Apr, 2026 |
| Jeffrey A Rona | Cbfo | 156,313 | 0 | 02 Mar, 2026 |
| Jeffrey A Rona | Cbfo | 156,313 | 0 | 02 Mar, 2026 |
| Margaret A. Alexander | President And Ceo | 61,750 | 0 | 02 Mar, 2026 |
| Jason Tardio | Chief Operating Officer | 28,125 | 0 | 26 Feb, 2024 |
| Thomas Michael Perone | General Counsel, Secretary | 28,125 | 0 | 26 Feb, 2024 |
| Jason Tardio | Chief Operating Officer | 28,125 | 0 | 26 Feb, 2024 |
| Thomas Michael Perone | General Counsel, Secretary | 28,125 | 0 | 26 Feb, 2024 |
| Kevin Joseph Fitzgerald | - | 17,578 | 0 | 09 Apr, 2026 |
| Bart Friedman | - | 8,789 | 0 | 09 Apr, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 07 Apr, 2026 | Kevin Joseph Fitzgerald | Common Stock | A | 17,578 | $2.56 | 17,578 | D | A |
| 07 Apr, 2026 | Bart Friedman | Common Stock | A | 8,789 | $2.56 | 8,789 | D | A |
| 07 Apr, 2026 | Stelios Papadopoulos | Common Stock | A | 17,578 | $2.56 | 217,578 | D | A |
| 23 Mar, 2026 | Jeremy M Levin | Common Stock | A | 47,333 | $1.40 | 3,735,048 | D | M |
| 23 Mar, 2026 | Jeremy M Levin | Series A Warrant (right to buy) | D | 47,333 | $0.00 | 0 | D | M |
| 26 Feb, 2026 | Karen Bernstein | Employee Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 26 Feb, 2026 | Kevin Joseph Fitzgerald | Employee Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 23 Feb, 2026 | Margaret A. Alexander | Common Stock | D | 11,656 | $1.45 | 61,750 | D | S |
| 26 Feb, 2026 | Barbara Gayle Duncan | Employee Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 23 Feb, 2026 | Jeffrey A Rona | Common Stock | D | 8,541 | $1.45 | 88,188 | D | S |
| 23 Feb, 2026 | Jeffrey A Rona | Common Stock | D | 8,541 | $1.45 | 88,188 | D | S |
| 26 Feb, 2026 | Stelios Papadopoulos | Employee Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 26 Feb, 2026 | Jeremy M Levin | Employee Stock Option (Right to Buy) | A | 957,000 | $0.00 | 957,000 | D | A |
| 26 Feb, 2026 | Bart Friedman | Employee Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 26 Feb, 2026 | Jeffrey A Rona | Common Stock | A | 68,125 | $0.00 | 156,313 | D | A |
| 26 Feb, 2026 | Jeffrey A Rona | Common Stock | A | 68,125 | $0.00 | 156,313 | D | A |
| 26 Feb, 2026 | Margaret A. Alexander | Employee Stock Option (Right to Buy) | A | 1,435,000 | $0.00 | 1,435,000 | D | A |
| 26 Feb, 2026 | Jeffrey A Rona | Employee Stock Option (Right to Buy) | A | 408,750 | $0.00 | 408,750 | D | A |
| 26 Feb, 2026 | Jeffrey A Rona | Employee Stock Option (Right to Buy) | A | 408,750 | $0.00 | 408,750 | D | A |
| 04 Jan, 2026 | Margaret A. Alexander | Employee Stock Option (right to buy) | A | 890,000 | $0.00 | 890,000 | D | A |